» Articles » PMID: 38474021

Epigenetic Regulation of EMP/EMT-Dependent Fibrosis

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Mar 13
PMID 38474021
Authors
Affiliations
Soon will be listed here.
Abstract

Fibrosis represents a process characterized by excessive deposition of extracellular matrix (ECM) proteins. It often represents the evolution of pathological conditions, causes organ failure, and can, in extreme cases, compromise the functionality of organs to the point of causing death. In recent years, considerable efforts have been made to understand the molecular mechanisms underlying fibrotic evolution and to identify possible therapeutic strategies. Great interest has been aroused by the discovery of a molecular association between epithelial to mesenchymal plasticity (EMP), in particular epithelial to mesenchymal transition (EMT), and fibrogenesis, which has led to the identification of complex molecular mechanisms closely interconnected with each other, which could explain EMT-dependent fibrosis. However, the result remains unsatisfactory from a therapeutic point of view. In recent years, advances in epigenetics, based on chromatin remodeling through various histone modifications or through the intervention of non-coding RNAs (ncRNAs), have provided more information on the fibrotic process, and this could represent a promising path forward for the identification of innovative therapeutic strategies for organ fibrosis. In this review, we summarize current research on epigenetic mechanisms involved in organ fibrosis, with a focus on epigenetic regulation of EMP/EMT-dependent fibrosis.

Citing Articles

Application of an Integrated Single-Cell and Three-Dimensional Spheroid Culture Platform for Investigating Drug Resistance Heterogeneity and Epithelial-Mesenchymal Transition (EMT) in Lung Cancer Subclones.

Chen S, Yu J, Lin Y, Chang Y, Liu N, Chen S Int J Mol Sci. 2025; 26(4).

PMID: 40004228 PMC: 11855057. DOI: 10.3390/ijms26041766.


The role of epithelial-mesenchymal transition in pulmonary fibrosis: lessons from idiopathic pulmonary fibrosis and COVID-19.

Niayesh-Mehr R, Kalantar M, Bontempi G, Montaldo C, Ebrahimi S, Allameh A Cell Commun Signal. 2024; 22(1):542.

PMID: 39538298 PMC: 11558984. DOI: 10.1186/s12964-024-01925-y.

References
1.
Liang Y, He L, Yuan H, Jin Y, Yao Y . Association between RUNX3 promoter methylation and non-small cell lung cancer: a meta-analysis. J Thorac Dis. 2014; 6(6):694-705. PMC: 4073407. DOI: 10.3978/j.issn.2072-1439.2014.04.09. View

2.
Liu Y, Wen D, Ho C, Yu L, Zheng D, OReilly S . Epigenetics as a versatile regulator of fibrosis. J Transl Med. 2023; 21(1):164. PMC: 9983257. DOI: 10.1186/s12967-023-04018-5. View

3.
Chen L, Alam A, Pac-Soo A, Chen Q, Shang Y, Zhao H . Pretreatment with valproic acid alleviates pulmonary fibrosis through epithelial-mesenchymal transition inhibition in vitro and in vivo. Lab Invest. 2021; 101(9):1166-1175. PMC: 8367813. DOI: 10.1038/s41374-021-00617-2. View

4.
Geisler S, Coller J . RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol. 2013; 14(11):699-712. PMC: 4852478. DOI: 10.1038/nrm3679. View

5.
Liang H, Xu C, Pan Z, Zhang Y, Xu Z, Chen Y . The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis. Mol Ther. 2014; 22(6):1122-1133. PMC: 4048895. DOI: 10.1038/mt.2014.42. View